Scholarlink

<p>In transcatheter closure of patent foramen ovale (PFO) associated with cryptogenic stroke (CS), a small coexisting atrial septal defect (ASD) can serve as a potential source of residual shunting if not adequately addressed. We conducted a retrospective study of 14 patients with PFO and coexisting ASD who underwent transcatheter closure between December 2019 and May 2025. The first five patients treated with Amplatzer™ PFO Occluder demonstrated residual right-to-left shunting graded ≥ 3 at one-year follow-up. Following the introduction of the GORE® CARDIOFORM Septal Occluder (GSO) and GORE® CARDIOFORM ASD Occluder (GCA) in Japan, nine additional patients were treated. Among the eight patients who completed one-year follow-up, seven exhibited no significant residual right-to-left shunting (i.e., grade &lt; 3). No recurrent strokes or device-related complications occurred in any of the 14 patients. This single-center study highlights the importance of appropriate device selection in managing PFO and coexisting ASD. In this anatomically complex subset, the use of GSO and GCA was associated with more favorable anatomical closure outcomes. However, these results should be interpreted cautiously in light of the limited number of cases and the non-comparative study design.</p> Graphic abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Percutaneous closure strategy in patients with patent foramen ovale and coexisting small atrial septal defect: a single-center experience

  • 期刊论文

  • 发表日期：

    2026年5月30日

查看全文
  • Mai Kimura,
  • Hideaki Kanazawa,
  • Masaki Kodaira,
  • Keitaro Shinada,
  • Kohsuke Shirakawa,
  • Yohei Numasawa,
  • Yoshikane Izawa,
  • Hikaru Tsuruta,
  • Kentaro Hayashida,
  • Masaki Ieda

摘要

In transcatheter closure of patent foramen ovale (PFO) associated with cryptogenic stroke (CS), a small coexisting atrial septal defect (ASD) can serve as a potential source of residual shunting if not adequately addressed. We conducted a retrospective study of 14 patients with PFO and coexisting ASD who underwent transcatheter closure between December 2019 and May 2025. The first five patients treated with Amplatzer™ PFO Occluder demonstrated residual right-to-left shunting graded ≥ 3 at one-year follow-up. Following the introduction of the GORE® CARDIOFORM Septal Occluder (GSO) and GORE® CARDIOFORM ASD Occluder (GCA) in Japan, nine additional patients were treated. Among the eight patients who completed one-year follow-up, seven exhibited no significant residual right-to-left shunting (i.e., grade < 3). No recurrent strokes or device-related complications occurred in any of the 14 patients. This single-center study highlights the importance of appropriate device selection in managing PFO and coexisting ASD. In this anatomically complex subset, the use of GSO and GCA was associated with more favorable anatomical closure outcomes. However, these results should be interpreted cautiously in light of the limited number of cases and the non-comparative study design.

Graphic abstract